ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1106

The Impact of Gender on Inpatient Mortality of Hypertensive Patients with CKD3 to ESRD in the US

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Nader, Mark Abi, Kidney Care Consultants, Memphis, Tennessee, United States
  • Aguilar Campos, Rodrigo, Georgetown University Hospital, Washington, District of Columbia, United States
  • Hassan, Oussama, Royal London Hospital, Austin, Texas, United States
  • Cervantes, Carmen Elena, Aventura Hospital and Medical Center, Aventura, Florida, United States
  • Correa, Ricardo, University of Arizona, Phoenix, Arizona, United States
  • Sharma, Prabin, Yale University Bridgeport Hospital, Bridgeport, Connecticut, United States
  • Shafique, Rehan, Kidney Care Consultants, Memphis, Tennessee, United States
  • Vo, Hieu Q., university of Tennessee, Memphis, Tennessee, United States
  • Hamze, Omar, Kidney Care Consultants, Memphis, Tennessee, United States
  • Li, Ping, George Washington University, Washington, District of Columbia, United States
  • Gordon, Judit, Medstar Georgeotown University Hospital, Washington, District of Columbia, United States

HTN and CKD are 2 of the most important risk factors for CVD in the US population.The impact of gender or race in this equation remains unclear. Studies comparing the inpatient mortality between males and females with HTN and CKD are sparse. Our aim was to determine if gender in the US population and menopausal age, affect the inpatient survival rate of hypertensive patients across CKD stages.


Data was extracted from the 2005-2012 Nationwide Inpatient Sample (NIS). Using propensity score matching, hypertensive female with CKD (stage3-5 + ESRD) patients were matched with hypertensive males at a 1:1 ratio. We compared inpatient mortality per CKD stage, menopausal age and race. Analyses were performed using SAS9.3.


Among 2,121,750 hospitalized hypertensive patients, 51.5% were males and 48.5% females. There was 32.1% females with CKD3, 14.7% with CKD4, 3.4% CKD5 and 54% with ESRD. Similarly, 32.7% of males have CKD3, 13.2% CKD4, 3.2% CKD5 and 50.9% with ESRD. In-hospital crude mortality was significantly higher for males compared to females at CKD stages 3 (3.1 vs 3.3% p<0.0001), CKD4 (4.1 vs 4.4%p=0.0004) and ESRD (5.1 vs 5.2%p=0.0039) but was non-significant in CKD5 not on dialysis (4.7 vs 4.8%p=0.45). Factoring menopausal age for each race group, we find women<50y old to have significantly less mortality than men, across all CKD stages and races. Women> 50y have similar mortality rate to men with CKD 3,4 or 5; while women>50y with ESRD have a significantly higher mortality than ESRD men of similar race group (fig1).


Inpatient mortality risk of women compared to men through stages of CKD 3 to ESRD, appears to be reduced in pre-menopausal women, comparable after menopause and increased when on dialysis, irrespective of the race group. Further studies are needed to elucidate the possible links of menopause and the effect of gender with mortality in patients with hypertension and CKD and to assess if this holds true in outpatient settings.